UHRF1 promotes epithelial-mesenchymal transition in renal tubular epithelial cells by driving G2/M phase arrest through activating the TGF-β/Smad signaling pathway
Аннотация
Diabetic kidney disease is a major cause of chronic kidney disease, and persistent activation of transforming growth factor-β/Smad signaling contributes to tubulointerstitial fibrosis. The epigenetic regulator UHRF1 has been implicated in renal fibrosis, but its role in sustaining transforming growth factor-β signaling remains unclear. To investigate whether UHRF1 promotes transforming growth factor-β1-induced epithelial-mesenchymal transition in tubular epithelial cells through a DNMT1/Smad7-dependent mechanism. Human HK-2 tubular epithelial cells were stimulated with transforming growth factor-β1. UHRF1 was overexpressed or silenced to evaluate effects on viability, apoptosis, migration, cell-cycle distribution, profibrotic mediator secretion, and epithelial-mesenchymal transition marker expression. Rescue experiments were performed using Smad7 overexpression and the transforming growth factor-β receptor inhibitor SB431542. DNMT-family specificity was additionally assessed by co-immunoprecipitation of UHRF1 with DNMT1, DNMT3A, and DNMT3B. UHRF1 overexpression aggravated transforming growth factor-β1-induced epithelial-mesenchymal transition, apoptosis, migration, G2/M phase arrest, and profibrotic mediator production, whereas UHRF1 silencing attenuated these changes. Mechanistically, UHRF1 recruited DNMT1 to the Smad7 promoter, suppressed Smad7 expression, and sustained Smad2/3 phosphorylation. Restoration of Smad7 or inhibition of transforming growth factor-β signaling reversed the effects mediated by UHRF1. In the DNMT-family specificity analysis, DNMT1, but not DNMT3A or DNMT3B, was detected in UHRF1 immunoprecipitates under the tested conditions. UHRF1 promotes epithelial-mesenchymal transition in tubular epithelial cells by sustaining transforming growth factor-β/Smad signaling through epigenetic repression of Smad7. The DNMT-family comparison supports a preferential UHRF1–DNMT1 association in this experimental system. Clinical trial registration: Not applicable.